ArticleBMC women's health2025
Cervical cancer screening: comparative study of human papillomavirus detection between cervical cytology and urine samples.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Agreement and Diagnostic Performance of Urinary HPV Testing Versus Clinician-Collected Cervico-Vaginal Sampling: A Prospective Cross-Sectional Study in a Romanian Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Clinical value of first-morning urine exfoliated cell HPV detection in the diagnosis of high-grade cervical lesions.Frontiers in oncology · 2026Article
- Comparative performance of hrHPV testing and PAX1/ZNF671 methylation in triaging women with abnormal cytology: a study of paired urine, vaginal and cervical scrape samples.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of urine-based human papillomavirus detection in detecting high-grade cervical lesions (CIN2+) compared to cervical cytology examination.
methodThe data of 458 patients with cytological abnormalities and/or positive human papillomavirus test results were retrospectively selected from December 1, 2017, to March 31, 2022, at the Beijing Obstetrics and Gynecology Hospital affiliated with Capital Medical University. Cervical cytology and urine samples were used to detect human papillomavirus status and analyze the correlation between the results and cervical biopsy results.
resultsAmong the selected 458 samples, 386 were positive for human papillomavirus through cervical cytology examination, with a detection rate of 84.3%. Out of 458 urine samples, 362 were positive, with a detection rate of 79.0%. The data shows a high consistency between cervical cytology and urine sample testing, with a kappa value of 0.637 (P < 0.01). The most prevalent subtypes in cervical samples included HPV16, HPV58, and HPV52, while the detection rates of HPV16 and HPV58 subtypes were relatively high in urine samples. The comparison of subtype distribution between cervical and urine samples showed that the positivity rate of HPV44 subtype was consistent, both at 3.9%. Among the five HPV subtypes corresponding to the HPV nine-valent vaccine, the kappa value of HPV16 in cervical and urine samples was 0.791 (P < 0.05), the kappa value of HPV52 was 0.766 (P < 0.05), HPV18 was 0.762 (P < 0.05), HPV33 was 0.539 (P < 0.01), and HPV31 was 0.458 (P < 0.05). Among 458 specimens, the sensitivity of human papillomavirus detection in cervical cytology was 96.7%, with a specificity of 20.2% (P < 0.01). The sensitivity of human papillomavirus detection in urine samples was 85.2%, with a specificity of 23.2% (P < 0.01).
conclusionUrine human papillomavirus testing, as a non-invasive screening method, has significant application effects. The screening results are highly consistent with cervical cytology screening and may improve the compliance of women who do not want to undergo invasive gynecological examinations. This screening method simplifies the screening process and has great potential in screening cancer lesions and preventing cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.